Press Releases

LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution

Todd Durniak brings deep industry expertise in diabetes and medical device industry, with track record of successful product launches

Jul 1, 2015

CAESAREA, Israel, July 1, 2015 /PRNewswire/ -- LabStyle Innovations Corp. (DRIO), developer of the Dario™ Diabetes Management Solution, today announced the appointment of Todd Durniak as Senior Vice President and General Manager for the U.S.  Durniak brings to LabStyle over 20 years of medical device commercial and technical leadership, most recently as the Vice President and General Manager of Neighborhood Diabetes, a division of Insulet focused on delivering insulin supplies through durable medical equipment (DME) and pharmacy channels with a 'high touch' training approach. 

"The U.S. is a very important and strategic market for us. Todd's vast experience in commercializing new products and services in the medical device, and specifically the diabetes market, make him the right person to lead our U.S. market launch.  He shares our vision of how Dario can transform the treatment of diabetes and he has the industry expertise and relationships to execute on making this a reality in the U.S.," stated LabStyle President and Chief Executive Officer, Erez Raphael.

"I am very excited about the Dario's smartphone-based technology and it's potential to impact the lives of individuals and their caregivers, along with physicians and payers," commented Durniak.  "I believe my experience in sales, distribution, pharmacy, and customer service operations, along with diabetic disease management, is a strong fit for successfully launching Dario to the U.S market."

Prior to Insulet and Neighborhood Diabetes, Durniak held a number of positions of increasing responsibility over 7 years at Smith & Nephew Orthopedics, most recently as President, Asia Pacific, based in Sydney, Australia.  Durniak began his career in engineering with Johnson & Johnson Orthopedics, leaving to start and manage Texas Direct Medical, an orthopedic product distributorship.  He later re-joined Johnson & Johnson post the acquisition of DePuy, moving through a series of positions before joining Guidant just prior to its acquisition by Boston Scientific. Durniak holds a BS of Engineering in Biomedical Engineering from the University of Vermont and an MBA from Boston University.

LabStyle has filed a 510K application with the U.S. Food and Drug Administration for marketing approval of the Dario™ in the U.S. The Dario is already approved and launched in Canada, the United Kingdom, New Zealand, Australia, Israel and the Netherlands.

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB: DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ Diabetes Management Solution. Dario™ empowers people with diabetes to take charge of their health with the right tools, insights, and support in their pocket.  With access to both real-time and historical blood glucose data, Dario™ is designed to spot patterns, recommend the right treatments and support behavior change efforts.

Dario™ is a platform that combines an all-in-one, blood glucose meter, smart phone application (iOS & Android), website application and treatment tools to support more proactive and better informed decisions by patients, doctors and healthcare systems. The stylish and compact self-monitoring system combines a lancet to obtain a blood sample, a proprietary disposable test strip cartridge and a smartphone-driven glucose meter. LabStyle Innovations is led by an experienced management team with vast software, medical device and technology experience and is guided by a world class board of directors and scientific advisory board. For more information: and

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss that Dario can transform the treatment of diabetes, or when we discuss successfully launching Dario to the U.S. market. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Press and Investor Relations
Brenda Zeitlin 
LabStyle Innovations 
1 800 896 9062


SOURCE LabStyle Innovations Corp.